Authors
Latest:
Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 InsertionErminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Latest:
Technology Drives Biomarker Testing Rates in Precision OncologyThe knowledge gained from biomarker testing can help develop cancer prevention, diagnosis, and treatment strategies that specifically target a person’s cancer subtype.
Latest:
What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.
Latest:
Implications of the MEDIOLA Trial Results in Relapsed Ovarian CancerSusana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.
Latest:
Relationship Between Plaque Psoriasis and Cancer Risk IdentifiedIn a retrospective study, investigators assessed the risk of development a malignancy in patients with psoriasis. Findings showed that select patients with psoriasis have a higher risk cancer risk.
Latest:
Dizman Insights on Improving ASCO's Language of Respect in RCCNazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.
Latest:
Evaluating Camu Camu With Ipilimumab and Nivolumab in mRCCRegina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.
Latest:
Patients' Social Needs Remain Critical During Cancer TreatmentPuneeth Indurlal, MD, MS, discusses the implications of assessing for patients' health-related social needs during the course of cancer treatment at the 2024 ASCO Annual Meeting.
Latest:
Genetic Testing Empowers Better Cancer Care, Prevention, and Early DetectionToday, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.
Latest:
Advancing the Perioperative Management of Bladder CancerFollowing the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.
Latest:
Key Telehealth Factors to MonitorWhen providing telehealth, providers must check individual state laws and policies regarding telehealth and providing telehealth across state lines. In sum, there is a lot to stay on top of in relation to telehealth.
Latest:
INDIGO Trial Shows Potential of Vorasidenib in Low-Grade GliomaKatherine B. Peters, MD, PhD, discusses the findings from the phase 3 INDIGO trial which were presented at the 2023 ASCO annual meeting.
Latest:
Reflections on Immunotherapies for Hematologic Malignancies From MCI’s Fifth Annual SummitGuenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.
Latest:
Algorithm-Based Referrals Increase Palliative Care for Advanced Cancer PatientsRavi Parikh, MD, MPP, discusses findings and implications of a study exploring algorithm-based palliative care recommendations.
Latest:
Final Analysis of ELM-2 Shows Promise of Odronextamab in R/R DLBCLSabarish Ram Ayyappan, MD, discusses findings from the final analysis of the phase 2 ELM-2 trial of odronextamab in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Frailty May Impact Hospital Stay Duration After Stem Cell TransplantsKayla Giannetti, MSN, APRN-CNP, discusses a study presented at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigating the link between patient frailty and stem cell transplants.
Latest:
Opinions on Treatment Split for Prominent Questions in Bladder CancerMatthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.
Latest:
Overcoming Resistance in Gastrointestinal CancersImmune checkpoint inhibitors are approved for dMMR/MSI-H gastrointestinal cancer treatment; however, approximately half of patients with dMMR/MSI-H gastrointestinal cancer exhibit primary resistance to them.
Latest:
The Promise of Pragmatic Innovation in Community OncologyNini Wu, MD, MBA, highlights practical technology in community oncology and how it is used to enhance patient and staff experiences.
Latest:
Kidney Cancer Awareness Month: The Evolving Landscape of RCC ManagementRobert Galamaga, DO, reviews single-agent and combination targeted therapy advances in renal cell carcinoma for Kidney Cancer Awareness Month.
Latest:
Liquid Biopsies Enhance PSMA-Directed Therapies in GU CancersJacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.
Latest:
Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHDUday R. Popat, MD, discusses the role of ruxolitinib as treatment of patients with graft-versus-host-disease.
Latest:
Pevonedistat/Azacitidine Combo Demonstrates Encouraging EFS Data in Phase 2 Trial in MDSJustin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.
Latest:
Solutions Are Emerging to Help MIDs Efficiently Manage Prior AuthorizationsMedically integrated dispensing pharmacies in oncology often deal with complex PAs that can inhibit delivery of timely, quality care and consume staff resources.
Latest:
BTK Inhibitor Therapy Can Be Stopped in CLLThe decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.
Latest:
Apalutamide Produces Deep PSA Response vs Enzalutamide in mCSPCBenjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.
Latest:
Overcoming Atypical EGFR Challenges With a Novel ApproachByoung Chul Cho, MD, PhD, discusses the implications of the CHRYSALIS-2 study of amivantamab and lazertinib.
